Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aegerion Pharmaceuticals, Inc.

Latest From Aegerion Pharmaceuticals, Inc.

Bespoke Gene Therapy ‘Playbook’ Outlines Platform Approach To AAV-Based Treatments

Supporting ‘n of 1’ gene therapy development, the playbook from a Foundation for the National Institutes of Health-backed consortium aims to help investigators who are not traditional product sponsors prepare for meetings with US FDA and IND submissions.

Gene Therapy Clinical Trials

VBP Pains Swell Prompting New China Strategy, Local Innovation Focus

As the rollout of volume-based procurement to more products brings more pain, drug makers are exploring different China strategies. One indicator, though, is clear - local innovation and distribution can’t be ignored anymore.

China Commercial

Sanofi/AstraZeneca Resolving Beyfortus Shortage By Reallocating Southern Hemisphere Supply

With the White House putting a spotlight on US shortages of their new RSV monoclonal antibody, Sanofi and AstraZeneca can take some solace that the negative headlines stem from unexpectedly high demand and easier reimbursement for the immunization than the companies’ predicted.

Manufacturing Vaccines

MTI 100 Outlook 2024: Shaping An Environment Where Technology Leads The Way

Compliance with greenhouse gas reduction targets is not optional for medtech businesses who, besides the bigger picture, have their own sustainability to think of. Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation. In the EU, the MDR is also having an effect on innovation strategies.

Medtech 100 Policy
See All

Company Information